<div>
<h2>Key Points</h2><ul><li>ACT Capital Management sold 38,500 shares of Structure Therapeutics in the first quarter; the estimated transaction value was $2.63 million based on Q1 2026 average prices.</li><li>The quarter-end position value decreased by $2.68 million, reflecting both the sale and stock price movement.</li><li>The transaction represented 2.07% of reported 13F assets under management (AUM).</li><li>10 stocks we like better than Structure Therapeutics ›</li></ul><p>On May 8, 2026, ACT Capital Management reported selling all 38,500 shares of <strong>Structure Therapeutics</strong> <span class="ticker">(NASDAQ:GPCR)</span>, an estimated $2.63 million trade based on quarterly average pricing.</p><h2 id="what-happened">What happened</h2><p>According to its SEC filing dated May 8, 2026, ACT Capital Management fully exited its position in Structure Therapeutics during the first quarter. The fund sold all 38,500 shares, with the estimated transaction value at $2.63 million based on the average closing price for the quarter. The net position change, which includes both trading and price effects, was a $2.68 million decrease. The fund now reports no shares in the company.</p><h2 id="what-else-to-know">What else to know</h2><ul><li>ACT Capital Management fully exited its Structure Therapeutics stake during the quarter.</li><li>Top holdings after the filing:<ul><li>NASDAQ: KRYS: $15.62 million (12.3% of AUM)</li><li>NYSE: CVX: $15.52 million (12.2% of AUM)</li><li>NYSE: XOM: $11.88 million (9.3% of AUM)</li><li>NASDAQ: CELC: $10.46 million (8.2% of AUM)</li><li>NASDAQ: TGTX: $8.27 million (6.5% of AUM)</li></ul></li><li>As of May 7, 2026, shares of Structure Therapeutics were priced at $39.15, up 47% over the past year and outperforming the S&amp;P 500 by about 17 percentage points.</li></ul><h2 id="company-overview">Company overview</h2><section><table><tbody><tr><th>Metric</th><th>Value</th></tr><tr><td>Price (as of market close May 7, 2026)</td><td>$39.15</td></tr><tr><td>Market Capitalization</td><td>$2.8 billion</td></tr><tr><td>Net Income (TTM)</td><td>($141.2 million)</td></tr></tbody></table></section><h2 id="company-snapshot">Company snapshot</h2><ul><li>Structure Therapeutics develops oral therapeutics for chronic diseases, including lead candidate GSBR-1290 for type-2 diabetes and obesity, and additional candidates targeting pulmonary and cardiovascular conditions.</li><li>The company operates a clinical-stage biopharmaceutical model focused on proprietary small-molecule drug development, with revenue potential driven by future product approvals and commercialization.</li><li>It targets patients with chronic metabolic, pulmonary, and cardiovascular diseases, aiming to address unmet medical needs in large global markets.</li></ul><p>Structure Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of novel oral small-molecule therapeutics for chronic diseases with significant unmet needs. The company leverages expertise in G-protein-coupled receptor (GPCR) drug targets to advance candidates in metabolic, pulmonary, and cardiovascular indications. Its strategy centers on innovation in oral drug design, aiming to provide differentiated therapies in competitive, high-growth markets.</p><h2 id="what-this-transaction-means-for-investors">What this transaction means for investors</h2><p>Structure Therapeutics shares have climbed about 47% over the past year, and ACT Capital appears to have decided the easier money may already have been made, especially with biotech volatility still elevated across the GLP-1 space.<br/><br/>That said, the company’s underlying momentum remains hard to ignore. Just this week, Structure reported positive Phase 2 data for aleniglipron, its oral GLP-1 drug candidate, showing up to 16.3% placebo-adjusted weight loss at 44 weeks. Management said the efficacy potentially compares favorably with injectable GLP-1 therapies and remains on track to launch a Phase 3 program in the third quarter.<br/><br/>The balance sheet also gives the company room to execute. Structure ended the quarter with roughly $1.5 billion in cash, cash equivalents, and short-term investments, which management says should fund operations through the end of 2028.<br/><br/>With all this in mind, this sale ultimately looks less like a loss of confidence in Structure Therapeutics and more like a disciplined exit after a massive run in obesity-drug names. Hiccups in data releases could challenge the stock, but it’s impossible to ignore the momentum in the obesity drug market.</p><h2>Should you buy stock in Structure Therapeutics right now?</h2>
<p>Before you buy stock in Structure Therapeutics, consider this:</p>
<p>The <em>Motley Fool Stock Advisor</em> analyst team just identified what they believe are the <strong>10 best stocks</strong> for investors to buy now… and Structure Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.</p>
<p>Consider when <strong>Netflix</strong> made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, <strong>you’d have $471,827</strong>!* Or when <strong>Nvidia</strong> made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, <strong>you’d have $1,319,291</strong>!*</p>
<p>Now, it’s worth noting <em>Stock Advisor’s</em> total average return is 986<span>% — a market-crushing outperformance compared to 207% for the S&amp;P 500. <strong><span>Don't miss the latest top 10 list, available with <em>Stock Advisor</em>, and join an investing community built by individual investors for individual investors.</span></strong></span></p>
<p>See the 10 stocks »</p>
<p style="color: #767676; text-align: left"><em>*Stock Advisor returns as of May 10, 2026. </em></p><p><em>Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chevron and Krystal Biotech. The Motley Fool recommends TG Therapeutics. The Motley Fool has a disclosure policy.</em></p>
<p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
</div>

GPCR

LABU

SBIO

ARKG

<p>ACT Capital Management fully exited its position in Structure Therapeutics, selling 38,500 shares valued at approximately $2.63 million. This sale occurred in Q1 2026, coinciding with a 47% increase in Structure's stock price over the past year. Despite the exit, the company reported positive Phase 2 data for its oral GLP-1 drug candidate, aleniglipron, and has a strong cash position of $1.5 billion, which supports future operations. Analysts suggest that while ACT's exit may reflect a disciplined decision, the underlying momentum in the obesity drug market remains significant.</p>

nasdaq

Structure Therapeutics

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Krystal Biotech

Chevron

Exxon Mobil

Celcuity

TG Therap

S&P 500

Netflix

NVIDIA

NVIDIA Corporation

Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position